As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Casita Feliz, a nonprofit serving the Latino LGBTQ+ community in Fresno, recently celebrated its one-year anniversary ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

Women – especially teen girls and young women living in sub-Saharan Africa – are disproportionately impacted by <a ...

Use of the anti-CD19 CAR T-cell therapy obecabtagene autoleucel (obe-cel; Aucatzyl) resulted in durable remissions among ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...